| Characteristic . | All n = 126 (100%) . | Received Remdesivir n = 54 (42.9%) . | Did Not Receive Remdesivir n = 72 (57.1%) . | P . |
|---|---|---|---|---|
| Sex—female, No. (%) | 72 (57.1) | 26 (48.1) | 46 (63.9) | .344 |
| Age, median (IQR), y | 49 (35–63) | 43 (31–61) | 51.5 (41.4–64.5) | <.001 |
| Obesity, No. (%) | 24 (19.1) | 10 (18.5) | 14 (19.4) | .896 |
| Type 2 diabetes mellitus, No. (%) | 27 (21.4) | 10 (18.5) | 17 (23.6) | .491 |
| Arterial hypertension, No. (%) | 40 (31.8) | 14 (25.9) | 26 (36.1) | .224 |
| Cerebrovascular disease, No. (%) | 4 (3.2) | 1 (1.9) | 3 (4.2) | .635 |
| Ischemic heart disease, No. (%) | 5 (4.0) | 2 (3.7) | 3 (4.2) | 1.000 |
| Chronic lung disease, No. (%) | 6 (4.8) | 3 (5.6) | 3 (4.2) | 1.000 |
| Advanced chronic kidney disease,a No. (%) | 9 (7.1) | 4 (7.4) | 5 (6.9) | .920 |
| Liver cirrhosis,a No. (%) | 6 (4.8) | 1 (1.9) | 5 (6.9) | .237 |
| Solid organ malignant neoplasm,a No. (%) | 9 (7.1) | 5 (9.3) | 4 (5.6) | .424 |
| Malignant hematologic disorders,a No. (%) | 15 (11.9) | 5 (9.3) | 10 (13.9) | .427 |
| Uncontrolled HIV infection,a No. (%) | 2 (1.6) | 0 (0) | 2 (2.8) | .506 |
| Autoimmune disorders,a No. (%) | 39 (31.0) | 16 (29.6) | 23 (31.9) | .781 |
| Solid organ transplant recipient,a No. (%) | 31 (24.6) | 13 (24.1) | 18 (25.0) | .905 |
| Hematopoietic stem cell transplant recipients,a No. (%) | 7 (5.6) | 4 (7.4) | 3 (4.2) | .461 |
| RT-PCR ct value, median (IQR), units (n = 117) | 23 (21–27) | 21 (23–26) n = 45 | 23.5 (20.5–28) n = 72 | .702 |
| Previous vaccination against SARS-CoV-2, No. (%) | 100 (79.4) | 45 (83.3) | 55 (76.4) | .340 |
| Previous SARS-CoV-2 infection, No. (%) | 19 (9.3) | 5 (9.3) | 14 (19.4) | .114 |
| Time from symptom onset to hospital presentation, median (range), d | 4 (0–7) | 3 (0–7) | 4 (1–7) | .82 |
| Time from symptom onset to remdesivir administration, median (range), d | … | 3 (0–7) | … |
| Characteristic . | All n = 126 (100%) . | Received Remdesivir n = 54 (42.9%) . | Did Not Receive Remdesivir n = 72 (57.1%) . | P . |
|---|---|---|---|---|
| Sex—female, No. (%) | 72 (57.1) | 26 (48.1) | 46 (63.9) | .344 |
| Age, median (IQR), y | 49 (35–63) | 43 (31–61) | 51.5 (41.4–64.5) | <.001 |
| Obesity, No. (%) | 24 (19.1) | 10 (18.5) | 14 (19.4) | .896 |
| Type 2 diabetes mellitus, No. (%) | 27 (21.4) | 10 (18.5) | 17 (23.6) | .491 |
| Arterial hypertension, No. (%) | 40 (31.8) | 14 (25.9) | 26 (36.1) | .224 |
| Cerebrovascular disease, No. (%) | 4 (3.2) | 1 (1.9) | 3 (4.2) | .635 |
| Ischemic heart disease, No. (%) | 5 (4.0) | 2 (3.7) | 3 (4.2) | 1.000 |
| Chronic lung disease, No. (%) | 6 (4.8) | 3 (5.6) | 3 (4.2) | 1.000 |
| Advanced chronic kidney disease,a No. (%) | 9 (7.1) | 4 (7.4) | 5 (6.9) | .920 |
| Liver cirrhosis,a No. (%) | 6 (4.8) | 1 (1.9) | 5 (6.9) | .237 |
| Solid organ malignant neoplasm,a No. (%) | 9 (7.1) | 5 (9.3) | 4 (5.6) | .424 |
| Malignant hematologic disorders,a No. (%) | 15 (11.9) | 5 (9.3) | 10 (13.9) | .427 |
| Uncontrolled HIV infection,a No. (%) | 2 (1.6) | 0 (0) | 2 (2.8) | .506 |
| Autoimmune disorders,a No. (%) | 39 (31.0) | 16 (29.6) | 23 (31.9) | .781 |
| Solid organ transplant recipient,a No. (%) | 31 (24.6) | 13 (24.1) | 18 (25.0) | .905 |
| Hematopoietic stem cell transplant recipients,a No. (%) | 7 (5.6) | 4 (7.4) | 3 (4.2) | .461 |
| RT-PCR ct value, median (IQR), units (n = 117) | 23 (21–27) | 21 (23–26) n = 45 | 23.5 (20.5–28) n = 72 | .702 |
| Previous vaccination against SARS-CoV-2, No. (%) | 100 (79.4) | 45 (83.3) | 55 (76.4) | .340 |
| Previous SARS-CoV-2 infection, No. (%) | 19 (9.3) | 5 (9.3) | 14 (19.4) | .114 |
| Time from symptom onset to hospital presentation, median (range), d | 4 (0–7) | 3 (0–7) | 4 (1–7) | .82 |
| Time from symptom onset to remdesivir administration, median (range), d | … | 3 (0–7) | … |
Abbreviations: ct, cycle threshold; IQR, interquartile range; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Indicates comorbidities considered to be immunocompromising.
| Characteristic . | All n = 126 (100%) . | Received Remdesivir n = 54 (42.9%) . | Did Not Receive Remdesivir n = 72 (57.1%) . | P . |
|---|---|---|---|---|
| Sex—female, No. (%) | 72 (57.1) | 26 (48.1) | 46 (63.9) | .344 |
| Age, median (IQR), y | 49 (35–63) | 43 (31–61) | 51.5 (41.4–64.5) | <.001 |
| Obesity, No. (%) | 24 (19.1) | 10 (18.5) | 14 (19.4) | .896 |
| Type 2 diabetes mellitus, No. (%) | 27 (21.4) | 10 (18.5) | 17 (23.6) | .491 |
| Arterial hypertension, No. (%) | 40 (31.8) | 14 (25.9) | 26 (36.1) | .224 |
| Cerebrovascular disease, No. (%) | 4 (3.2) | 1 (1.9) | 3 (4.2) | .635 |
| Ischemic heart disease, No. (%) | 5 (4.0) | 2 (3.7) | 3 (4.2) | 1.000 |
| Chronic lung disease, No. (%) | 6 (4.8) | 3 (5.6) | 3 (4.2) | 1.000 |
| Advanced chronic kidney disease,a No. (%) | 9 (7.1) | 4 (7.4) | 5 (6.9) | .920 |
| Liver cirrhosis,a No. (%) | 6 (4.8) | 1 (1.9) | 5 (6.9) | .237 |
| Solid organ malignant neoplasm,a No. (%) | 9 (7.1) | 5 (9.3) | 4 (5.6) | .424 |
| Malignant hematologic disorders,a No. (%) | 15 (11.9) | 5 (9.3) | 10 (13.9) | .427 |
| Uncontrolled HIV infection,a No. (%) | 2 (1.6) | 0 (0) | 2 (2.8) | .506 |
| Autoimmune disorders,a No. (%) | 39 (31.0) | 16 (29.6) | 23 (31.9) | .781 |
| Solid organ transplant recipient,a No. (%) | 31 (24.6) | 13 (24.1) | 18 (25.0) | .905 |
| Hematopoietic stem cell transplant recipients,a No. (%) | 7 (5.6) | 4 (7.4) | 3 (4.2) | .461 |
| RT-PCR ct value, median (IQR), units (n = 117) | 23 (21–27) | 21 (23–26) n = 45 | 23.5 (20.5–28) n = 72 | .702 |
| Previous vaccination against SARS-CoV-2, No. (%) | 100 (79.4) | 45 (83.3) | 55 (76.4) | .340 |
| Previous SARS-CoV-2 infection, No. (%) | 19 (9.3) | 5 (9.3) | 14 (19.4) | .114 |
| Time from symptom onset to hospital presentation, median (range), d | 4 (0–7) | 3 (0–7) | 4 (1–7) | .82 |
| Time from symptom onset to remdesivir administration, median (range), d | … | 3 (0–7) | … |
| Characteristic . | All n = 126 (100%) . | Received Remdesivir n = 54 (42.9%) . | Did Not Receive Remdesivir n = 72 (57.1%) . | P . |
|---|---|---|---|---|
| Sex—female, No. (%) | 72 (57.1) | 26 (48.1) | 46 (63.9) | .344 |
| Age, median (IQR), y | 49 (35–63) | 43 (31–61) | 51.5 (41.4–64.5) | <.001 |
| Obesity, No. (%) | 24 (19.1) | 10 (18.5) | 14 (19.4) | .896 |
| Type 2 diabetes mellitus, No. (%) | 27 (21.4) | 10 (18.5) | 17 (23.6) | .491 |
| Arterial hypertension, No. (%) | 40 (31.8) | 14 (25.9) | 26 (36.1) | .224 |
| Cerebrovascular disease, No. (%) | 4 (3.2) | 1 (1.9) | 3 (4.2) | .635 |
| Ischemic heart disease, No. (%) | 5 (4.0) | 2 (3.7) | 3 (4.2) | 1.000 |
| Chronic lung disease, No. (%) | 6 (4.8) | 3 (5.6) | 3 (4.2) | 1.000 |
| Advanced chronic kidney disease,a No. (%) | 9 (7.1) | 4 (7.4) | 5 (6.9) | .920 |
| Liver cirrhosis,a No. (%) | 6 (4.8) | 1 (1.9) | 5 (6.9) | .237 |
| Solid organ malignant neoplasm,a No. (%) | 9 (7.1) | 5 (9.3) | 4 (5.6) | .424 |
| Malignant hematologic disorders,a No. (%) | 15 (11.9) | 5 (9.3) | 10 (13.9) | .427 |
| Uncontrolled HIV infection,a No. (%) | 2 (1.6) | 0 (0) | 2 (2.8) | .506 |
| Autoimmune disorders,a No. (%) | 39 (31.0) | 16 (29.6) | 23 (31.9) | .781 |
| Solid organ transplant recipient,a No. (%) | 31 (24.6) | 13 (24.1) | 18 (25.0) | .905 |
| Hematopoietic stem cell transplant recipients,a No. (%) | 7 (5.6) | 4 (7.4) | 3 (4.2) | .461 |
| RT-PCR ct value, median (IQR), units (n = 117) | 23 (21–27) | 21 (23–26) n = 45 | 23.5 (20.5–28) n = 72 | .702 |
| Previous vaccination against SARS-CoV-2, No. (%) | 100 (79.4) | 45 (83.3) | 55 (76.4) | .340 |
| Previous SARS-CoV-2 infection, No. (%) | 19 (9.3) | 5 (9.3) | 14 (19.4) | .114 |
| Time from symptom onset to hospital presentation, median (range), d | 4 (0–7) | 3 (0–7) | 4 (1–7) | .82 |
| Time from symptom onset to remdesivir administration, median (range), d | … | 3 (0–7) | … |
Abbreviations: ct, cycle threshold; IQR, interquartile range; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Indicates comorbidities considered to be immunocompromising.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
